GLUCOCORTICOID SPARING EFFECT OF THE BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHUMATOID ARTHRITIS IN TUNISIAN REAL LIFE PRACTICE

R. Faikajath, H. Zeglaoui, N. El Amri, S. Hamila, N. Amara, K. Baccouche, E. Bouajina on behalf of BINAR, Farhat Hached Hospital, Rheumatology, Sousse, Tunisia

Background: Glucocorticoids (GCs) are still widely prescribed in rheumatoid arthritis (RA). Despite their disease-modifying properties, they are associated with significant adverse effects. The international guidelines recommend the lowest effective dose and the lowest duration of GCs. Previous studies have shown that biologic disease modifying anti-rheumatic drugs (bDMARDs) can have a GC-sparing effect in RA.

Objectives: The aim of the study was to assess the impact of the bDMARDs on glucocorticoid use in rheumatoid arthritis Tunisian patients, in real life practice.

Methods: RA patients (according to the American College of Rheumatology criteria) who started their first bDMARDs (Tumour necrosis factor (TNF) inhibitors, Tocilizumab and Rituximab) between January 2016 and August 2019, were recruited from the BINAR= Biologic National Registry, a prospective national Tunisian biologic registry. Oral prednisone intakes were compared at inclusion (M0), at 3 months (M3) and at 6 months (M6) after bDMARDs initiation.

Results: 175 patients were included (149 females / 26 males). The median age was 54.1 years ± 12.6 and the mean disease duration was 6.7 years ± 3.5. The TNF inhibitors, the Tocilizumab and the Rituximab were prescribed, respectively, in 79.4%, 17.7% and 8.6%. The mean DAS28 index activity was 4.9 ± 1.5 at M0, 4.5 ± 1.5 at M3 and 4.2 ± 1.1 at M6 (p<0.05). At inclusion, 150 patients (85.7%) were taking oral prednisone and the mean dose was 8.2 ± 1.5 at M0, 4.5 ± 1.5 at M3 and 4.2 ± 1.1 at M6 (p<0.05). The mean DAS28 index activity was 3.5. The TNF inhibitors, the Tocilizumab and the Rituximab were prescribed, respectively, in 79.4%, 17.7% and 8.6%. The mean daily dose of oral prednisone was 8.9 ± 4.3 mg at M3 (p<0.05) and 8.1 ± 2.7 mg at M6 (P=0.05). At M3 and M6, 4% and 2% of patients (p>0.05) had lowered prednisone doses, respectively. Prednisone discontinuation was observed in 17.7% at M3 and 18.1% at M6. Increased prednisone doses were noted in 2.7% at M3 and 2.6% at M6. The bDMARDs use wasn’t associated with oral prednisone decrease at M3 (TNFα inhibitors p=0.51; Tocilizumab p=0.54; Rituximab p=0.77) and at M6 (TNFα inhibitors p=0.61; Tocilizumab p=0.39; Rituximab p=0.64).

Conclusion: This study showed a small glucocorticoids sparing-effect of bDMARDs at 3 months and 6 months in rheumatoid arthritis patients with a decrease of oral prednisone use of 18.1% at 3 months.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6148

EFFICACY, SAFETY AND IMMUNOGENICITY IN PATIENTS WITH RHUMATOID ARTHRITIS COMPARING PF-06410293 (ADL-PF), AN ADALIMUMAB (ADL) BIOSIMILAR, AND REFERENCE ADL: RESULTS FROM WEEK 26–52 OF A DOUBLE-BLIND, RANDOMISED PHASE 3 STUDY INCLUDING PATIENTS WHO CHANGED OR SWITCHED FROM ADL-PF TO REFERENCE ADL AT WEEK 26

R. Fleischmann1, D. Alvarez2, A. Bock3, C. Cronenberger2, I. Vranic1, W. Zhang4, R. Allen5, University of Texas, Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, United States of America; 1Pfizer Inc, Collegeville, United States of America; 2Pfizer Inc, Cambridge, United States of America; 3Pfizer, Tadworth, United Kingdom; 4Pfizer Inc, Lake Forest, United States of America; 5Schlosspark Klinik, University Medicine, Berlin, Germany

Background: PF-06410293 (ADL-PF) is an adalimumab biosimilar approved for the treatment of several inflammatory and autoimmune indications.1 The efficacy, safety and immunogenicity of ADL-PF and reference adalimumab sourced from the European Union (ADL-EU) in patients with rheumatoid arthritis (RA) have been demonstrated to be similar in a randomised controlled trial up to 26 weeks; treatment period 1 (TP1).2

Objectives: To evaluate the efficacy, safety and immunogenicity of ADL-PF and ADL-EU in patients with moderate to severe RA on longer-term treatment, and following a treatment switch from ADL-EU to ADL-PF in a subset of patients.

Methods: This multinational, randomised, double-blind, parallel-group study compared ADL-PF and ADL-EU in essentially biologic-naive patients with active RA despite methotrexate (MXT) (NCT02480153). In TP1, patients were randomised (1:1) to ADL-PF or ADL-EU (40 mg subcutaneous injection every 2 wks) for 26 wks while continuing MXT (10–25 mg/wk). The primary endpoint was achievement of American College of Rheumatology response (ACR20) at Wk 12. At Wk 26, the start of treatment period 2 (TP2), patients receiving ADL-EU were blindly re-randomised (1:1) to remain on ADL-EU or switch to ADL-PF for 26 wks while patients receiving ADL-PF continued treatment in a blinded manner. Secondary efficacy endpoints at Wks 26, 30, 36, 44 and 52 (ACR20 /50/70, European League Against Rheumatism [EULAR] response, Disease Activity Score [DAS] 28-4[CRP] ≥2.6 and ACR/EULAR defined remission), safety events and percentage of patients with anti-drug antibodies (ADA) were assessed.

Results: In TP1, 597 patients were randomised to ADL-PF (n=297) or ADL-EU (n=300). At Wk 26, 552 patients were re-randomised for TP2 (continued ADL-PF, n=283; continued ADL-EU, n=135; switched from ADL-EU to ADL-PF, n=134). Patients who demonstrated at least minimal efficacy continued in TP2. Observed ACR20 rates were comparable between treatment groups at all visits during TP2 (Figure). Other measures of deep response (ACR70, EULAR good response, DAS28-4[CRP] ≥2.6 and ACR/EULAR defined remission) showed maintained efficacy during TP2 in all treatment groups. Incidences of treatment-emergent adverse events were comparable between treatment groups (Table). Overall, incidences of ADA through Wk 52 were comparable between treatment groups (47.3%, 54.1% and 45.9% for patients who continued ADL-PF, continued ADL-EU or switched from ADL-EU to ADL-PF, respectively). In patients who switched from ADL-EU to ADL-PF compared with patients who continued ADL-EU, the increase in ADA incidence over TP2 was 0.8% (from 45.1% to 45.9%) versus 6.7% (from 47.4% to 54.1%), respectively.

Conclusion: TP2 results demonstrated comparable efficacy, safety and immunogenicity between ADL-PF and ADL-EU was maintained up to Wk 52 and was unaffected by a blinded switch from ADL-EU to ADL-PF at Wk 26.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6149